Ameriprise
MRNA icon

Ameriprise’s Moderna MRNA Stock Holding History

Ameriprise’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.72M Sell
138,731
-4,718
-3% -$244K ﹤0.01% 2077
2026
Q1 		$7.29M Sell
143,449
-74,611
-34% -$3.48M ﹤0.01% 2176
2025
Q4 		$6.43M Sell
218,060
-123,217
-36% -$3.35M ﹤0.01% 2253
2025
Q3 		$8.82M Buy
341,277
+186,094
+120% +$5.19M ﹤0.01% 2010
2025
Q2 		$4.28M Sell
155,183
-45,060
-23% -$1.19M ﹤0.01% 2478
2025
Q1 		$5.68M Sell
200,243
-35,037
-15% -$1.24M ﹤0.01% 2222
2024
Q4 		$9.78M Buy
235,280
+23,007
+11% +$1.1M ﹤0.01% 1824
2024
Q3 		$14.2M Sell
212,273
-77,091
-27% -$7.08M ﹤0.01% 1530
2024
Q2 		$34.4M Sell
289,364
-9,293
-3% -$1.18M 0.01% 977
2024
Q1 		$31.8M Sell
298,657
-539
-0.2% -$54.3K 0.01% 1023
2023
Q4 		$29.7M Buy
299,196
+2,744
+0.9% +$231K 0.01% 1039
2023
Q3 		$30.6M Buy
296,452
+12,504
+4% +$1.39M 0.01% 982
2023
Q2 		$34.5M Sell
283,948
-4,859
-2% -$648K 0.01% 943
2023
Q1 		$44.4M Buy
288,807
+21,924
+8% +$3.62M 0.01% 806
2022
Q4 		$47.9M Buy
266,883
+44,468
+20% +$7.27M 0.02% 744
2022
Q3 		$26.3M Sell
222,415
-23,796
-10% -$3.61M 0.01% 1017
2022
Q2 		$35.1M Sell
246,211
-36,707
-13% -$5.25M 0.01% 879
2022
Q1 		$47.6M Sell
282,918
-28,324
-9% -$4.77M 0.01% 829
2021
Q4 		$75.4M Buy
311,242
+69,045
+29% +$20.2M 0.02% 666
2021
Q3 		$93.2M Buy
242,197
+51,284
+27% +$18.9M 0.03% 543
2021
Q2 		$44.9M Sell
190,913
-14,067
-7% -$2.51M 0.01% 844
2021
Q1 		$26.9M Sell
204,980
-126,865
-38% -$18.4M 0.01% 1104
2020
Q4 		$34.6M Buy
331,845
+79,756
+32% +$8.07M 0.01% 910
2020
Q3 		$17.8M Sell
252,089
-33,446
-12% -$2.33M 0.01% 1149
2020
Q2 		$18.3M Sell
285,535
-18,408
-6% -$1.01M 0.01% 1106
2020
Q1 		$9.1M Buy
303,943
+15,663
+5% +$360K ﹤0.01% 1455
2019
Q4 		$5.64M Sell
288,280
-116,758
-29% -$2.07M ﹤0.01% 2163
2019
Q3 		$6.44M Buy
405,038
+367,198
+970% +$5.42M ﹤0.01% 2028
2019
Q2 		$555K Buy
+37,840
New +$813K ﹤0.01% 3296

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Ameriprise's MRNA Position: Q2 2026 in Review

Ameriprise reduced its Moderna (MRNA) stake by 3.3% in Q2 2026, selling an estimated $244K and leaving 138,731 shares worth $9.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

Ameriprise first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $93.2M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Ameriprise held 138,731 shares of Moderna worth $9.72M as of Q2 2026.
  • Ameriprise sold 4,718 Moderna shares in Q2 2026, an estimated $244K.
  • Moderna made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2077 holding.
  • Ameriprise first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • Ameriprise's Moderna position peaked at $93.2M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.